P1101 (Ropeginterferon alfa-2b)
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polycythemia Vera (PV)
Conditions
Polycythemia Vera (PV)
Trial Timeline
Jan 19, 2021 → Jun 30, 2026
NCT ID
NCT04655092About P1101 (Ropeginterferon alfa-2b)
P1101 (Ropeginterferon alfa-2b) is a phase 3 stage product being developed by PharmaEssentia for Polycythemia Vera (PV). The current trial status is recruiting. This product is registered under clinical trial identifier NCT04655092. Target conditions include Polycythemia Vera (PV).
What happened to similar drugs?
2 of 16 similar drugs in Polycythemia Vera (PV) were approved
Approved (2) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04655092 | Phase 3 | Recruiting |
Competing Products
20 competing products in Polycythemia Vera (PV)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sapablursen + Placebo | Ono Pharmaceutical | Phase 3 | 47 |
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 36 |
| Bomedemstat | Merck | Phase 2 | 35 |
| Ruxolitinib + Hydroxycarbamide + Interferon-Alpha | Novartis | Phase 3 | 47 |
| ruxolitinib tablets | Novartis | Phase 3 | 40 |
| Ruxolitinib | Novartis | Pre-clinical | 26 |
| Ruxolitinib | Novartis | Phase 3 | 40 |
| Ruxolitinib + BAT | Novartis | Phase 2 | 39 |
| Hydroxyurea | Novartis | Approved | 35 |
| Best Available Therapy + Ruxolitinib | Novartis | Phase 3 | 40 |
| Smac Mimetic LCL161 | Novartis | Phase 2 | 35 |
| PEGASYS + Aspirin | Roche | Phase 2 | 35 |
| RG7388 + Pegasys | Roche | Phase 1 | 29 |
| Idasanutlin | Roche | Phase 2 | 27 |
| PEGASYS + Hydroxyurea + Aspirin | Roche | Phase 3 | 40 |
| Ropeginterferon alfa-2b | PharmaEssentia | Phase 2 | 39 |
| Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen | PharmaEssentia | Phase 3 | 40 |
| Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT) | PharmaEssentia | Phase 3 | 40 |
| Ropeginterferon alfa-2b | PharmaEssentia | Approved | 50 |
| P1101 + Low-dose aspirin | PharmaEssentia | Phase 2 | 35 |